請用此 Handle URI 來引用此文件：
http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/85125完整後設資料紀錄
| DC 欄位 | 值 | 語言 |
|---|---|---|
| dc.contributor.advisor | 江伯倫(Bor-Luen Chiang) | |
| dc.contributor.author | Cheng-Tsung Yang | en |
| dc.contributor.author | 楊政宗 | zh_TW |
| dc.date.accessioned | 2023-03-19T22:45:12Z | - |
| dc.date.copyright | 2022-10-03 | |
| dc.date.issued | 2022 | |
| dc.date.submitted | 2022-08-10 | |
| dc.identifier.citation | 1. Chen CH, Lin YT, Wen CY, et al. Quantitative assessment of allergic shiners in children with allergic rhinitis. J Allergy Clin Immunol, 2009. 123(3): p. 665-71, 671.e1-6. 2. Marks MB. Allergic shiners. Dark circles under the eyes in children. Clin Pediatr (Phila), 1966. 5(11): p. 655-8. 3. Friedmann DP, Goldman MP. Dark circles: etiology and management options. Clin Plast Surg, 2015. 42(1): p. 33-50. 4. Shah-Desai S, Joganathan V. Novel technique of non-surgical rejuvenation of infraorbital dark circles. J Cosmet Dermatol, 2021. 20(4): p. 1214-20. 5. Barone CR, Boza JC, Machado PG, et al. Association between clinical characteristics, quality of life, and sleep quality in patients with periorbital hyperchromia. J Cosmet Dermatol, 2019. 18(1): p. 230-5. 6. Verschoore M, Gupta S, Sharma VK, et al. Determination of melanin and haemoglobin in the skin of idiopathic cutaneous hyperchromia of the orbital region (ICHOR): A study of Indian patients. J Cutan Aesthet Surg, 2012. 5(3): p. 176-82. 7. Freitag FM, Cestari TF. What causes dark circles under the eyes? J Cosmet Dermatol, 2007. 6(3): p. 211-5. 8. Roh MR, Chung KY. Infraorbital dark circles: definition, causes, and treatment options. Dermatol Surg, 2009. 35(8): p. 1163-71. 9. Sheth PB, Shah HA, Dave JN. Periorbital hyperpigmentation: a study of its prevalence, common causative factors and its association with personal habits and other disorders. Indian J Dermatol, 2014. 59(2): p. 151-7. 10. Ranu H, Thng S, Goh BK, et al. Periorbital hyperpigmentation in Asians: an epidemiologic study and a proposed classification. Dermatol Surg, 2011. 37(9): p. 1297-303. 11. Nkengne A, Bertin C, Stamatas GN, et al. Influence of facial skin attributes on the perceived age of Caucasian women. J Eur Acad Dermatol Venereol, 2008. 22(8): p. 982-91. 12. Mac-Mary S, Zornoza Solinis I, Predine O, et al. Identification of three key factors contributing to the aetiology of dark circles by clinical and instrumental assessments of the infraorbital region. Clin Cosmet Investig Dermatol, 2019. 12: p. 919-29. 13. Fabi S, Alexiades M, Chatrath V, et al. Facial aesthetic priorities and concerns: A physician and patient perception global survey. Aesthet Surg J, 2022. 42(4): p. NP218-29. 14. Stutman RL, Codner MA. Tear trough deformity: review of anatomy and treatment options. Aesthet Surg J, 2012. 32(4): p. 426-40. 15. Hill DA, Grundmeier RW, Ram G, et al. The epidemiologic characteristics of healthcare provider-diagnosed eczema, asthma, allergic rhinitis, and food allergy in children: a retrospective cohort study. BMC Pediatr, 2016. 16: p. 133. 16. Hirmand H. Anatomy and nonsurgical correction of the tear trough deformity. Plast Reconstr Surg, 2010. 125(2): p. 699-708. 17. Chopra K, Calva D, Sosin M, et al. A comprehensive examination of topographic thickness of skin in the human face. Aesthet Surg J, 2015. 35(8): p. 1007-13. 18. Vrcek I, Ozgur O, Nakra T. Infraorbital dark circles: A review of the pathogenesis, evaluation and treatment. J Cutan Aesthet Surg, 2016. 9(2): p. 65-72. 19. Camp MC, Wong WW, Filip Z, et al. A quantitative analysis of periorbital aging with three-dimensional surface imaging. J Plast Reconstr Aesthet Surg, 2011. 64(2): p. 148-54. 20. Lai L, Casale TB, Stokes J. Pediatric allergic rhinitis: treatment. Immunol Allergy Clin North Am, 2005. 25(2): p. 283-99, vi. 21. Chuan MT, Tsai TF, Wu MC, et al. Atrophic pigmented dermatofibrosarcoma presenting as infraorbital hyperpigmentation. Dermatology, 1997. 194(1): p. 65-7. 22. Goren SB. Eye disorders: common ocular injuries: assessing the severity. Postgrad Med, 1975. 58(7): p. 99-102. 23. Park KY, Kwon HJ, Youn CS, et al. Treatments of infra-orbital dark circles by various etiologies. Ann Dermatol, 2018. 30(5): p. 522-8. 24. Goodman RM, Belcher RW. Periorbital hyperpigmentation. An overlooked genetic disorder of pigmentation. Arch Dermatol, 1969. 100(2): p. 169-74. 25. Amini F, Thazin Oo NM, Okechukwu PN, et al. Polymorphisms in P53 and VEGFA genes in different subtypes of periorbital hyperpigmentation in a Malaysian Chinese population. Australas J Dermatol, 2019. 60(2): p. e99-e104. 26. Evans AG, Ivanic MG, Botros MA, et al. Rejuvenating the periorbital area using platelet-rich plasma: a systematic review and meta-analysis. Arch Dermatol Res, 2021. 313(9): p. 711-27. 27. Ransom ER, Stong BC, Jacono AA. Persistent improvement in lower eyelid-cheek contour after a transtemporal midface lift. Aesthetic Plast Surg, 2012. 36(6): p. 1277-82. 28. Nakra T. Biplanar contour-oriented approach to lower eyelid and midface rejuvenation. JAMA Facial Plast Surg, 2015. 17(5): p. 374-81. 29. Pessa JE, Zadoo VP, Mutimer KL, et al. Relative maxillary retrusion as a natural consequence of aging: combining skeletal and soft-tissue changes into an integrated model of midfacial aging. Plast Reconstr Surg, 1998. 102(1): p. 205-12. 30. Epstein JS. Management of infraorbital dark circles. A significant cosmetic concern. Arch Facial Plast Surg, 1999. 1(4): p. 303-7. 31. Huang YL, Chang SL, Ma L, et al. Clinical analysis and classification of dark eye circle. Int J Dermatol, 2014. 53(2): p. 164-70. 32. Watanabe S, Nakai K, Ohnishi T. Condition known as 'dark rings under the eyes' in the Japanese population is a kind of dermal melanocytosis which can be successfully treated by Q-switched ruby laser. Dermatol Surg, 2006. 32(6): p. 785-9; discussion 789. 33. Garcia A, Fulton JE, Jr. The combination of glycolic acid and hydroquinone or kojic acid for the treatment of melasma and related conditions. Dermatol Surg, 1996. 22(5): p. 443-7. 34. Newcomer VD, Lindberg MC, Sternberg TH. A melanosis of the face ('chloasma'). Arch Dermatol, 1961. 83: p. 284-99. 35. Manuskiatti W, Fitzpatrick RE, Goldman MP. Treatment of facial skin using combinations of CO2, Q-switched alexandrite, flashlamp-pumped pulsed dye, and Er:YAG lasers in the same treatment session. Dermatol Surg, 2000. 26(2): p. 114-20. 36. Goldberg RA, McCann JD, Fiaschetti D, et al. What causes eyelid bags? Analysis of 114 consecutive patients. Plast Reconstr Surg, 2005. 115(5): p. 1395-402; discussion 1403-4. 37. Sarkar R, Ranjan R, Garg S, et al. Periorbital hyperpigmentation: A comprehensive review. J Clin Aesthet Dermatol, 2016. 9(1): p. 49-55. 38. Sarkar R, Das A. Periorbital hyperpigmentation: What lies beneath? Indian Dermatol Online J, 2018. 9(4): p. 229-30. 39. Fatin AM, Mathana Sundram TK, Tan SSE, et al. Classification and characteristics of periorbital hyperpigmentation. Skin Res Technol, 2020. 26(4): p. 564-70. 40. Tan Y, Jiang Y, Chen J, et al. Establishment of visual assessment for the severity of dark circles in Chinese Han women. Skin Res Technol, 2021. 27(6): p. 1023-8. 41. Lim HGY, Fischer AH, Sung S, et al. Periocular dark circles: Correlates of severity. Ann Dermatol, 2021. 33(5): p. 393-401. 42. Ramakrishnan S, Hegde SP, Shenoy MM, et al. A cross-sectional study on clinico-dermoscopic features of periorbital melanosis in a tertiary care hospital. J Cosmet Dermatol, 2021. 20(9): p. 2917-23. 43. Paraskevas LR, Halpern AC, Marghoob AA. Utility of the Wood's light: five cases from a pigmented lesion clinic. Br J Dermatol, 2005. 152(5): p. 1039-44. 44. Chandrashekar BS, Soumya S. Effectiveness and safety of topical under-eye serum in patients with periorbital hyperpigmentation: An open-label single arm prospective study. J Clin Aesthet Dermatol, 2022. 15(2): p. 18-22. 45. Kang BK, Shin MK, Lee JH, et al. Effects of platelet-rich plasma on wrinkles and skin tone in Asian lower eyelid skin: preliminary results from a prospective, randomised, split-face trial. Eur J Dermatol, 2014. 24(1): p. 100-1. 46. Nkengne A, Robic J, Seroul P, et al. SpectraCam®: A new polarized hyperspectral imaging system for repeatable and reproducible in vivo skin quantification of melanin, total hemoglobin, and oxygen saturation. Skin Res Technol, 2018. 24(1): p. 99-107. 47. O'Mahony MM, Sladen C, Crone M, et al. A validated photonumeric scale for infraorbital dark circles and its application in evaluating the efficacy of a cosmetic treatment product in a split-face randomized clinical trial. Int J Cosmet Sci, 2021. 43(1): p. 48-56. 48. Mehryan P, Zartab H, Rajabi A, et al. Assessment of efficacy of platelet-rich plasma (PRP) on infraorbital dark circles and crow's feet wrinkles. J Cosmet Dermatol, 2014. 13(1): p. 72-8. 49. Du Y, Doraiswamy C, Mao J, et al. Facial skin characteristics and concerns in Indonesia: A cross-sectional observational study. Skin Res Technol, 2022. Epub ahead of print. 50. Graziosi AC, Quaresma MR, Michalany NS, et al. Cutaneous idiopathic hyperchromia of the orbital region (CIHOR): a histopathological study. Aesthetic Plast Surg, 2013. 37(2): p. 434-8. 51. Gendler EC. Treatment of periorbital hyperpigmentation. Aesthet Surg J, 2005. 25(6): p. 618-24. 52. Starace M, Alessandrini A, Brandi N, et al. Use of nail dermoscopy in the management of melanonychia: Review. Dermatol Pract Concept, 2019. 9(1): p. 38-43. 53. Ohshima H, Takiwaki H. Evaluation of dark circles of the lower eyelid: comparison between reflectance meters and image processing and involvement of dermal thickness in appearance. Skin Res Technol, 2008. 14(2): p. 135-41. 54. Budania A, Mandal S, Pathania YS, et al. Comparing novel versus conventional technique of platelet-rich plasma therapy in periorbital hyperpigmentation: A randomized prospective split-face study. J Cosmet Dermatol, 2021. 20(10): p. 3245-52. 55. Park SR, Kim HJ, Park HK, et al. Classification by causes of dark circles and appropriate evaluation method of dark circles. Skin Res Technol, 2016. 22(3): p. 276-83. 56. Marks MB. Photo of eye depression In: Vaughan WT, Black JR, editors. Practice of allergy. Philadelphia: C.V. Mosby Co, 1954: p. 1023. 57. Marks MB. Nasal allergy in childhood. Ann Allergy, 1960. 18: p. 1110-6. 58. Prenner BM, Schenkel E. Allergic rhinitis: treatment based on patient profiles. Am J Med, 2006. 119(3): p. 230-7. 59. Quillen DM, Feller DB. Diagnosing rhinitis: allergic vs. nonallergic. Am Fam Physician, 2006. 73(9): p. 1583-90. 60. Berger WE. Allergic rhinitis in children : diagnosis and management strategies. Paediatr Drugs, 2004. 6(4): p. 233-50. 61. Brozek JL, Bousquet J, Agache I, et al. Allergic rhinitis and its impact on asthma (ARIA) guidelines-2016 revision. J Allergy Clin Immunol, 2017. 140(4): p. 950-8. 62. Wallace DV, Dykewicz MS, Bernstein DI, et al. The diagnosis and management of rhinitis: an updated practice parameter. J Allergy Clin Immunol, 2008. 122(2 Suppl): p. S1-84. 63. Ho CL, Wu WF. Risk factor analysis of allergic rhinitis in 6-8 year-old children in Taipei. PLoS One, 2021. 16(4): p. e0249572. 64. Wheatley LM, Togias A. Clinical practice. Allergic rhinitis. N Engl J Med, 2015. 372(5): p. 456-63. 65. Meng Y, Wang C, Zhang L. Advances and novel developments in allergic rhinitis. Allergy, 2020. 75(12): p. 3069-76. 66. Bartemes KR, Kita H. Roles of innate lymphoid cells (ILCs) in allergic diseases: The 10-year anniversary for ILC2s. J Allergy Clin Immunol, 2021. 147(5): p. 1531-47. 67. Peng YQ, Qin ZL, Fang SB, et al. Effects of myeloid and plasmacytoid dendritic cells on ILC2s in patients with allergic rhinitis. J Allergy Clin Immunol, 2020. 145(3): p. 855-67.e8. 68. Bousquet J, Van Cauwenberge P, Khaltaev N, et al. Allergic rhinitis and its impact on asthma. J Allergy Clin Immunol, 2001. 108(5 Suppl): p. S147-334. 69. Bousquet J, Schunemann HJ, Togias A, et al. Next-generation allergic rhinitis and its impact on asthma (ARIA) guidelines for allergic rhinitis based on grading of recommendations assessment, development and evaluation (GRADE) and real-world evidence. J Allergy Clin Immunol, 2020. 145(1): p. 70-80 e3. 70. Bousquet J, Devillier P, Arnavielhe S, et al. Treatment of allergic rhinitis using mobile technology with real-world data: The MASK observational pilot study. Allergy, 2018. 73(9): p. 1763-74. 71. Bousquet J, Meltzer EO, Couroux P, et al. Onset of action of the fixed combination intranasal azelastine-fluticasone propionate in an allergen exposure chamber. J Allergy Clin Immunol Pract, 2018. 6(5): p. 1726-1732 e6. 72. Bedard A, Basagana X, Anto JM, et al. Mobile technology offers novel insights into the control and treatment of allergic rhinitis: The MASK study. J Allergy Clin Immunol, 2019. 144(1): p. 135-43 e6. 73. van Cauwenberge P, Bachert C, Passalacqua G, et al. Consensus statement on the treatment of allergic rhinitis. European Academy of Allergology and Clinical Immunology. Allergy, 2000. 55(2): p. 116-34. 74. Wise SK, Lin SY, Toskala E, et al. International consensus statement on allergy and rhinology: Allergic rhinitis. Int Forum Allergy Rhinol, 2018. 8(2): p. 108-352. 75. Graf P, Enerdal J, Hallen H. Ten days' use of oxymetazoline nasal spray with or without benzalkonium chloride in patients with vasomotor rhinitis. Arch Otolaryngol Head Neck Surg, 1999. 125(10): p. 1128-32. 76. Wang MF, Lin HC, Wang YY, et al. Treatment of perennial allergic rhinitis with lactic acid bacteria. Pediatr Allergy Immunol, 2004. 15(2): p. 152-8. 77. Juniper EF, Howland WC, Roberts NB, et al. Measuring quality of life in children with rhinoconjunctivitis. J Allergy Clin Immunol, 1998. 101(2 Pt 1): p. 163-70. 78. Weiner JM, Abramson MJ, Puy RM. Intranasal corticosteroids versus oral H1 receptor antagonists in allergic rhinitis: systematic review of randomised controlled trials. BMJ, 1998. 317(7173): p. 1624-9. 79. Wilson A, Dempsey OJ, Sims EJ, et al. Evaluation of treatment response in patients with seasonal allergic rhinitis using domiciliary nasal peak inspiratory flow. Clin Exp Allergy, 2000. 30(6): p. 833-8. 80. Malm L. Pharmacological background to decongesting and anti-inflammatory treatment of rhinitis and sinusitis. Acta Otolaryngol Suppl, 1994. 515: p. 53-5; discussion 55-6. 81. Barnes ML, Biallosterski BT, Gray RD, et al. Decongestant effects of nasal xylometazoline and mometasone furoate in persistent allergic rhinitis. Rhinology, 2005. 43(4): p. 291-5. 82. Davis EC, Callender VD. Postinflammatory hyperpigmentation: a review of the epidemiology, clinical features, and treatment options in skin of color. J Clin Aesthet Dermatol, 2010. 3(7): p. 20-31. 83. Grimes PE. Management of hyperpigmentation in darker racial ethnic groups. Semin Cutan Med Surg, 2009. 28(2): p. 77-85. 84. Taylor S, Grimes P, Lim J, et al. Postinflammatory hyperpigmentation. J Cutan Med Surg, 2009. 13(4): p. 183-91. | |
| dc.identifier.uri | http://tdr.lib.ntu.edu.tw/jspui/handle/123456789/85125 | - |
| dc.description.abstract | 研究背景：黑眼圈的形成是由於血液或體液積累在眼睛下緣之上頜骨眶下溝。成因有許多，如鼻塞、鼻子發炎、眼睛發炎、臉部受傷或手術、和腫瘤形成等。在有過敏性鼻炎的兒童臉上，因為鼻塞造成靜脈回流不暢通，導致黑眼圈形成。過敏性黑眼圈（Allergic shiners）最早在1954年由Marks學者提出，在1963年，Marks更指出長期有過敏性鼻炎的兒童，會有更明顯的過敏性黑眼圈。此後，過敏性黑眼圈更廣泛地被視為在過敏性鼻炎兒童身上的一種重要的臨床表現。在2009年，台大醫院江伯倫教授和團隊率先創制以數位化影像和程式分析的方式去評估黑眼圈，並證實黑眼圈的顏色深淺和範圍大小與過敏疾病（如氣喘、過敏性鼻炎和異位性皮膚炎等）的嚴重度有相關。然而，有關過敏性鼻炎兒童在接受治療之後的黑眼圈變化的資料相當稀少。本研究首要目標是探討過敏性鼻炎的患童，在接受過敏性鼻炎的治療之後，其黑眼圈的顏色深淺和範圍大小是否也可以改善。次要目標是比較哪種過敏性鼻炎的治療能最有效地改善黑眼圈。 研究方法：招募6歲至12歲有中重度過敏性鼻炎的患童，並隨機分派至三組實驗組。第一組患童接受口服抗組織胺的治療，第二組接受合併類固醇鼻噴劑和口服抗組織胺的治療，第三組接受合併類固醇鼻噴劑和口服抗組織胺以及一週的血管收縮鼻噴劑的治療。在治療前和治療後的第七天、第十四天和第二十八天，受試兒童會接受標準化的數位影像拍攝，並回答兒童鼻結膜炎生活品質調查問卷（Pediatric Rhinoconjunctivitis Quality of Life Questionnaire， PRQLQ）。同時受試兒童的年齡、性別、有無合併其他過敏疾病、過敏性鼻炎的臨床症狀和嚴重度、相關的實驗室數據也會一併記錄。數位影像中的黑眼圈顏色深淺和範圍大小是交由無法獲知受試兒童資料的獨立研究人員分析。治療前後的資料在經過整理後，會進一步的分析和探討。 研究結果：從2020年1月至2022年4月，共有59位兒童參與研究。其中15位被分派至第一實驗組、11位至第二組、18位至第三組，並有15位患童被排除。針對首要研究目標，整體而言，過敏性鼻炎的治療不但能改善過敏性鼻炎，還能同時改善黑眼圈的大小。在治療後的28天，治療前後的黑眼圈的面積（the average area values of shiners，Aave）分別為1.32和1.13 cm2/m2（P = 0.016），有達到統計學上的差異。有關次要研究目標的結果，合併使用類固醇鼻噴劑和口服抗組織胺有或無再搭配一週的血管收縮鼻噴劑的治療可以有效縮小黑眼圈的面積大小。在第二實驗組，治療前為1.81 cm2/m2，治療後第28天為1.17 cm2/m2（P = 0.006）；在第三實驗組，治療前為1.25 cm2/m2，治療後第7天為0.95 cm2/m2（P = 0.021）。在群間比較的部分，在28天的治療之後，合併使用類固醇鼻噴劑和口服抗組織胺比單純只使用口服抗組織胺能更有效地使黑眼圈變小（Aave –0.35 cm2/m2, 95% CI, –0.67 to –0.03, P = 0.030）。另外，藥物醫囑遵從性好的受測兒童，其治療後黑眼圈大小改善的程度也比較好。在分派到合併使用類固醇鼻噴劑和口服抗組織胺治療的患童，若其藥物醫囑遵從性高，則其治療後的黑眼圈大小也會縮小比較多，彼此呈現中等程度的負相關（r = –0.402, P = 0.002）。此外，黑眼圈範圍大小的改善，也跟過敏性鼻炎鼻子症狀的改善呈現低度的正相關（r = 0.209, P = 0.028）。 結論：兒童過敏性鼻炎的治療，除了能改善過敏性鼻炎，也能改善黑眼圈大小。合併使用類固醇鼻噴劑和口服抗組織胺，能夠更有效地改善黑眼圈的大小。 | zh_TW |
| dc.description.abstract | Background: Allergic shiners are caused when blood and other fluids accumulate in the infraorbital groove. The correlation between the darkness and area values of allergic shiners and the severity of allergic rhinitis was documented. But no data revealed the reduction of allergic shiners after the relief of allergic rhinitis. The study aims to investigate whether the levels of allergic shiners could be alleviated by the treatments for children with allergic rhinitis. Methods: Children aged from 6 to 12 years old with moderate-severe allergic rhinitis were randomly assigned into three groups, including an oral antihistamine (OAH) alone group (group I), the combined a nasal corticosteroids (NCS) with an OAH group (group II), and the combined an NCS with an OAH plus a one-week nasal decongestant (ND) group (group III). A standardized digital photograph and the Pediatric Rhinoconjunctivitis Quality of Life Questionnaire (PRQLQ) were recorded at the beginning of the treatment, and on the 7th day, 14th day, and 28th day after treatment. The baseline levels of allergic shiners were compared with the data after treatment. Results: Fifty-nine children were recruited between Jan. 2020 to Apr. 2022, and fifteen were excluded or withdrawn. The remaining fifteen, eleven, and eighteen were assigned into group I, group II, and group III, respectively. Overall, nasal therapies improved the symptoms of allergic rhinitis as well as the area values of allergic shiners (Aave 1.32 vs 1.13 cm2/m2, P = 0.016) 28 days after treatment. In addition, the combined an NCS and an OAH with or without a one-week ND shrank allergic shiners remarkably (Aave 1.81 vs 1.17 cm2/m2, P = 0.006, in group II, on the 28th day after treatment; Aave 1.25 vs 0.95 cm2/m2, P = 0.021 in group III, on the 7th day after treatment, respectively). When compared with an OAH alone, the combined an NCS with an OAH was more efficacious in lessening allergic shiners (Aave –0.35 cm2/m2, 95% CI, –0.67 to –0.03, P = 0.030) 28 days after treatment. The reduction of the area values of allergic shiners disclosed a moderate correlation with the good adherence to the combined an NCS with an OAH (r = –0.402, P = 0.002), and a weak relationship between the improvement of nasal symptoms of allergic rhinitis (r = 0.209, P = 0.028). Conclusion: Nasal therapies alleviated not only the symptoms of allergic rhinitis but also the levels of allergic shiners in children. The application of a combination therapy is reasonable to provide a satisfying outcome in the clinic. | en |
| dc.description.provenance | Made available in DSpace on 2023-03-19T22:45:12Z (GMT). No. of bitstreams: 1 U0001-0808202217341200.pdf: 3168924 bytes, checksum: eb0ca2916b92dcb1eacde232034be337 (MD5) Previous issue date: 2022 | en |
| dc.description.tableofcontents | 口試委員會審定書................................................................ i 誌謝.......................................................................... ii 中文摘要...................................................................... iii 英文摘要....................................................................... v 目錄.......................................................................... vii 縮寫列表....................................................................... x 圖目錄......................................................................... xi 表目錄....................................................................... xiii Chapter 1. Introduction....................................................... 1 1.1 Overview of shiners..................................................... 1 1.1.1 Introduction of shiners................................................. 1 1.1.2 Epidemiology of shiners............................................. 1 1.1.3 The periorbital anatomy related to the shiners...................... 2 1.1.4 The etiology of shiners............................................. 3 1.1.5 Classification of shiners............................................. 5 1.1.6 Assessment of shiners................................................. 6 1.1.7 Therapeutic management of shiners..................................... 9 1.2 Allergic shiners and allergic rhinitis .................................. 10 1.2.1 Introduction of allergic shiners .................................. 10 1.2.2 Introduction of allergic rhinitis ................................. 11 1.2.3 Treatment of allergic rhinitis …................................... 11 1.3 Hypothesis and specific aims............................................. 13 Chapter 2. Methods........................................................... 14 2.1 Study design............................................................. 14 2.2 Randomization and assigned interventions..................................15 2.3 Standardized digital photography......................................... 16 2.4 Digital image analysis................................................... 16 2.5 Sample size.............................................................. 17 2.6 Statistical analysis..................................................... 18 Chapter 3. Results........................................................... 19 3.1 Patient characteristics.................................................. 19 3.2 Nasal therapies alleviated both allergic rhinitis and allergic shiners... 20 3.3 A combination therapy improved the symptoms of AR and the area values of AS more effectively........... 20 3.4 Better adherence to nasal therapies contributed to superior outcome............... 21 3.5 Well adherence to the combined an NCS with an OAH benefited the abatement of both AR and AS............. 23 3.6 The reduction of area values of AS correlated with the medication compliance and the improvement of symptoms of AR................. 24 3.7 Safety and adverse effects ............................................. 24 Chapter 4. Discussion....................................................... 26 4.1 Nasal therapies alleviate the levels of allergic shiners in children with allergic rhinitis........................................................... 26 4.2 The choice of medications in the three intervention groups.............. 26 4.3 Randomization in this study............................................. 27 4.4 Objective measurements in this study.................................... 28 4.5 The primary and secondary endpoints..................................... 28 4.6 The effectiveness of an NCS, an OAH, and an ND...................... 29 4.7 The difference between area values and darkness of shiners....... 30 4.8 The safety and side effects of an NCS, an OAH, and an ND....... 32 4.9 The limitations in this study........................................... 33 4.10 Conclusion............................................................. 34 參考文獻..................................................................... 35 圖............................................................................47 表........................................................................... 60 附錄1. Institutional review board certification.............................. 68 | |
| dc.language.iso | en | |
| dc.subject | 黑眼圈 | zh_TW |
| dc.subject | 過敏性鼻炎 | zh_TW |
| dc.subject | 數位分析技術 | zh_TW |
| dc.subject | 類固醇鼻噴劑 | zh_TW |
| dc.subject | infraorbital dark circles | en |
| dc.subject | allergic shiners | en |
| dc.subject | nasal corticosteroids | en |
| dc.subject | allergic rhinitis | en |
| dc.subject | digital-analyzed tool | en |
| dc.title | 改善過敏性鼻炎兒童黑眼圈之臨床研究 | zh_TW |
| dc.title | Study on nasal treatment on the levels of allergic shiners in children with allergic rhinitis | en |
| dc.type | Thesis | |
| dc.date.schoolyear | 110-2 | |
| dc.description.degree | 碩士 | |
| dc.contributor.author-orcid | 0000-0003-0130-3217 | |
| dc.contributor.advisor-orcid | 江伯倫(0000-0002-6705-0286) | |
| dc.contributor.oralexamcommittee | 葉德輝(Te-Huei Yeh),王麗潔(Li-Chieh Wang) | |
| dc.subject.keyword | 過敏性鼻炎,數位分析技術,類固醇鼻噴劑,黑眼圈, | zh_TW |
| dc.subject.keyword | allergic rhinitis,digital-analyzed tool,nasal corticosteroids,allergic shiners,infraorbital dark circles, | en |
| dc.relation.page | 68 | |
| dc.identifier.doi | 10.6342/NTU202202158 | |
| dc.rights.note | 同意授權(限校園內公開) | |
| dc.date.accepted | 2022-08-11 | |
| dc.contributor.author-college | 醫學院 | zh_TW |
| dc.contributor.author-dept | 臨床醫學研究所 | zh_TW |
| dc.date.embargo-lift | 2022-10-03 | - |
| 顯示於系所單位： | 臨床醫學研究所 | |
文件中的檔案：
| 檔案 | 大小 | 格式 | |
|---|---|---|---|
| U0001-0808202217341200.pdf 授權僅限NTU校內IP使用（校園外請利用VPN校外連線服務） | 3.09 MB | Adobe PDF |
系統中的文件，除了特別指名其著作權條款之外，均受到著作權保護，並且保留所有的權利。